Lindbrook Capital, LLC Tricida, Inc. Transaction History

Lindbrook Capital, LLC

5 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2022 Jan 24, 2023	SELL	$0.14 - $12.49 $38 - $3,447	-276 Reduced 71.32%	111 $0
Q3 2022 Nov 10, 2022	BUY	$8.51 - $13.6 $2,331 - $3,726	274 Added 242.48%	387 $4,000
Q2 2022 Aug 01, 2022	BUY	$7.31 - $11.85 $826 - $1,339	113 New	113 $1,000
Q4 2020 Jan 27, 2021	SELL	$4.37 - $9.46 $1,468 - $3,178	-336 Closed	0 $0
Q3 2020 Nov 03, 2020	BUY	$8.56 - $26.93 $2,876 - $9,048	336 New	336 $3,000

30K

124K

46.5K

Ticker TCDA
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 55,668,900
Market Cap $557K
Description
Tricida, Inc. operates as a pharmaceutical company. It focuses on the development and commercialization of veverimer (TRC101), a non-absorbed orally-administered polymer that has completed Phase III trial to treat metabolic acidosis in patients with chronic kidney disease by binding and removing acid from the gastrointestinal track. The company ...

Get notified when there are updates to the investment portfolio of Lindbrook Capital, LLC, based on Form 13F filings with the SEC.

Stay updated on Lindbrook Capital, LLC with notifications on news.